The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic Acid (Lidorestat) and Congeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications
Open accessAbstract
Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED(50)'s of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t(1/2), 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (C(max) in sciatic nerve and eye are 2.36 and 1.45 mug equiv/g, respectively, when dosed with [(14)C]lidorestat at 10 mg/kg po).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamada, Y., Araki, N., Koh, N., Nakamura, J., Horiuchi, S., & Hotta, N. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1695 · Cited by 169
Cited by
Benchmarking sets for molecular docking.
Huang, N., Shoichet, B. K., & Irwin, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608356 · Cited by 1,318
Keri, R. S., Patil, M. R., Patil, S. A., & Budagumpi, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.059 · Cited by 631
Diabetic Cataract—Pathogenesis, Epidemiology and Treatment
Pollreisz, A., & Schmidt-Erfurth, U. (2010) · Journal of Ophthalmology · doi:10.1155/2010/608751 · Cited by 418
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Medicinal significance of benzothiazole scaffold: an insight view
Sharma, P. C., Sinhmar, A., Sharma, A., Rajak, H., & Pathak, D. P. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.720572 · Cited by 256
Lagarde, N., Zagury, J.-F., & Montes, M. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00090 · Cited by 85
Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition
Liu, M., Qin, X., Li, J., Jiang, Y., Jiang, J., Guo, J., Xu, H., Wang, Y., Bi, H., & Wang, Z. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp05985e · Cited by 7
Metadata
- Authors
- Van Zandt, M. C., Jones, M. L., Gunn, D. E., Geraci, L. S., Jones, J. H., Sawicki, D. R., Sredy, J., Jacot, J. L., DiCioccio, A. T., Petrova, T., Mitschler, A., & Podjarny, A. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-03-30
- Volume
- 48
- Issue
- 9
- Pages
- 3141-3152
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2058149456
- Cited by
- 227
- References
- 1
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.